The bispecific antibody aimed at the vicious circle of IL-1β and IL-17A, is beneficial for the collagen-induced rheumatoid arthritis of mice through NF-κB signaling pathway

Aletaha, 2010, Rheumatoid arthritis classification criteria: an American college of rheumatology/european league against rheumatism collaborative initiative, Arthritis Rheum., 62, 2569, 10.1002/art.27584 van de Veerdonk, 2011, Inflammasome activation and IL-1beta and IL-18 processing during infection, Trends Immunol., 32, 110, 10.1016/j.it.2011.01.003 Navarro-Millan, 2013, Systematic review of tumor necrosis factor inhibitor discontinuation studies in rheumatoid arthritis, Clin. Ther., 35, 1850, 10.1016/j.clinthera.2013.09.015 Pease, 2011, Comparison of anti-TNF treatment initiation in rheumatoid arthritis databases demonstrates wide country variability in patient parameters at initiation of anti-TNF therapy, Semin. Arthritis Rheum., 41, 81, 10.1016/j.semarthrit.2010.09.004 Qi, 2012, A bispecific antibody against IL-1beta and IL-17A is beneficial for experimental rheumatoid arthritis, Int. Immunopharmacol., 14, 770, 10.1016/j.intimp.2012.10.005 Li, 2014, Therapeutic efficacy of three bispecific antibodies on collagen-induced arthritis mouse model, Int. Immunopharmacol., 21, 119, 10.1016/j.intimp.2014.04.018 Moon, 2010, Curcumin attenuates inflammatory response in IL-1beta-induced human synovial fibroblasts and collagen-induced arthritis in mouse model, Int. Immunopharmacol., 10, 605, 10.1016/j.intimp.2010.02.011 Burger, 2003, The active metabolite of leflunomide, A77 1726, inhibits the production of prostaglandin E2, matrix metalloproteinase 1 and interleukin 6 in human fibroblast-like synoviocytes, Rheumatology, 42, 89, 10.1093/rheumatology/keg038 Chao, 2011, Anti-IL-17A therapy protects against bone erosion in experimental models of rheumatoid arthritis, Autoimmunity, 44, 243, 10.3109/08916934.2010.517815 Zhang, 2013, Synergistic effects of interleukin-1beta and interleukin-17A antibodies on collagen-induced arthritis mouse model, Int. Immunopharmacol., 15, 199, 10.1016/j.intimp.2012.12.010 Sutton, 2009, Interleukin-1 and IL-23 induce innate IL-17 production from γδ t cells, amplifying th17 responses and autoimmunity, Immunity, 31, 331, 10.1016/j.immuni.2009.08.001 Lu, 2016, MicroRNA-125b-5p attenuates lipopolysaccharide-induced monocyte chemoattractant protein-1 production by targeting inhibiting LACTB in THP-1 macrophages, Arch. Biochem. Biophys., 590, 64, 10.1016/j.abb.2015.11.007 Shahrara, 2010, IL-17-mediated monocyte migration occurs partially through CC chemokine ligand 2/monocyte chemoattractant protein-1 induction, J. Immunol., 184, 4479, 10.4049/jimmunol.0901942 Bevaart, 2010, Evaluation of therapeutic targets in animal models of arthritis: how does it relate to rheumatoid arthritis?, Arthritis Rheum., 62, 2192, 10.1002/art.27503 Asquith, 2009, Animal models of rheumatoid arthritis, Eur. J. Immunol., 39, 2040, 10.1002/eji.200939578 Wang, 2007, Treatment with total alkaloids from Radix Linderae reduces inflammation and joint destruction in type II collagen-induced model for rheumatoid arthritis, J. Ethnopharmacol., 111, 322, 10.1016/j.jep.2006.11.031 Yu, 2015, Fibroblast growth factor 21 (FGF21) ameliorates collagen-induced arthritis through modulating oxidative stress and suppressing nuclear factor-kappa B pathway, Int. Immunopharmacol., 25, 74, 10.1016/j.intimp.2015.01.005 Dawson, 2003, Targeting monocyte chemoattractant protein-1 signalling in disease, Expert Opin. Ther. Targets, 7, 35, 10.1517/14728222.7.1.35 Edwards, 2009, Targeting the NF-kappaB pathway in asthma and chronic obstructive pulmonary disease, Pharmacol. Ther., 121, 1, 10.1016/j.pharmthera.2008.09.003 Pierce, 2009, Nuclear factor-{kappa}B activation contributes to vascular endothelial dysfunction via oxidative stress in overweight/obese middle-aged and older humans, Circulation, 119, 1284, 10.1161/CIRCULATIONAHA.108.804294 Huang, 2015, Deleterious effect of salusin-beta in paraventricular nucleus on sympathetic activity and blood pressure via NF-kappa B signaling in a rat model of obesity hypertension, Pharmazie, 70, 543 Firestein, 2003, Evolving concepts of rheumatoid arthritis, Nature, 423, 356, 10.1038/nature01661 Nam, 2010, Current evidence for the management of rheumatoid arthritis with biological disease-modifying antirheumatic drugs: a systematic literature review informing the EULAR recommendations for the management of RA, Ann. Rheum. Dis., 69, 976, 10.1136/ard.2009.126573 McInnes, 2007, Cytokines in the pathogenesis of rheumatoid arthritis, Nat. Rev. Immunol., 7, 429, 10.1038/nri2094 Kotake, 1999, IL-17 in synovial fluids from patients with rheumatoid arthritis is a potent stimulator of osteoclastogenesis, J. Clin. Invest., 103, 1345, 10.1172/JCI5703 Lubberts, 2004, Treatment with a neutralizing anti-murine interleukin-17 antibody after the onset of collagen-induced arthritis reduces joint inflammation, cartilage destruction, and bone erosion, Arthritis Rheum., 50, 650, 10.1002/art.20001 Jovanovic, 1998, IL-17 stimulates the production and expression of proinflammatory cytokines, IL-beta and TNF-alpha, by human macrophages, J. Immunol., 160, 3513, 10.4049/jimmunol.160.7.3513 Ehrenstein, 2004, Compromised function of regulatory T cells in rheumatoid arthritis and reversal by anti-TNFalpha therapy, J. Exp. Med., 200, 277, 10.1084/jem.20040165 Moller, 2006, Inhibition of IL-1, IL-6, and TNF-alpha in immune-mediated inflammatory diseases, Springer Semin. Immunopathol., 27, 391, 10.1007/s00281-006-0012-9 Feldmann, 2008, Role of cytokines in rheumatoid arthritis: an education in pathophysiology and therapeutics, Immunol. Rev., 223, 7, 10.1111/j.1600-065X.2008.00626.x Weinblatt, 2003, Adalimumab, a fully human anti-tumor necrosis factor α monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: the ARMADA trial, Arthritis Rheum., 48, 35, 10.1002/art.10697 Chabaud, 1998, Enhancing effect of IL-17 on IL-1-induced IL-6 and leukemia inhibitory factor production by rheumatoid arthritis synoviocytes and its regulation by Th2 cytokines, J. Immunol., 161, 409, 10.4049/jimmunol.161.1.409 Fossiez, 1996, T cell interleukin-17 induces stromal cells to produce proinflammatory and hematopoietic cytokines, J. Exp. Med., 183, 2593, 10.1084/jem.183.6.2593 Xu, 2015, Bi-specific antibodies with high antigen-binding affinity identified by flow cytometry, Int. Immunopharmacol., 24, 463, 10.1016/j.intimp.2014.12.011 Astry, 2011, A cytokine-centric view of the pathogenesis and treatment of autoimmune arthritis, J. Interferon Cytokine Res., 31, 927, 10.1089/jir.2011.0094 Taneja, 2015, Cytokines pre-determined by genetic factors are involved in pathogenesis of rheumatoid arthritis, Cytokine, 75, 216, 10.1016/j.cyto.2014.11.028 Saraiva, 2010, The regulation of IL-10 production by immune cells, Nat. Rev. Immunol., 10, 170, 10.1038/nri2711 Pestka, 2004, Interleukin-10 and related cytokines and receptors, Annu. Rev. Immunol., 22, 929, 10.1146/annurev.immunol.22.012703.104622 Manzanillo, 2015, Deciphering the crosstalk among IL-1 and IL-10 family cytokines in intestinal immunity, Trends Immunol., 36, 471, 10.1016/j.it.2015.06.003 Ma, 2016, IL-1beta siRNA adenovirus benefits liver regeneration by improving mesenchymal stem cells survival after acute liver failure, Ann. Hepatol., 15, 260 Chao, 2011, Anti-IL-17A therapy protects against bone erosion in experimental models of rheumatoid arthritis, Autoimmunity, 44, 243, 10.3109/08916934.2010.517815 Dinarello, 2004, Therapeutic strategies to reduce IL-1 activity in treating local and systemic inflammation, Curr. Opin. Pharmacol., 4, 378, 10.1016/j.coph.2004.03.010 Furst, 2004, Anakinra: review of recombinant human interleukin-I receptor antagonist in the treatment of rheumatoid arthritis, Clin. Ther., 26, 1960, 10.1016/j.clinthera.2004.12.019 Haringman, 2006, A randomized controlled trial with an anti-CCL2 (anti-monocyte chemotactic protein 1) monoclonal antibody in patients with rheumatoid arthritis, Arthritis Rheum., 54, 2387, 10.1002/art.21975 Henkel, 1993, Rapid proteolysis of I kappa B-alpha is necessary for activation of transcription factor NF-kappa B, Nature, 365, 182, 10.1038/365182a0 Hoffmann, 2002, The IkappaB-NF-kappaB signaling module: temporal control and selective gene activation, Science, 298, 1241, 10.1126/science.1071914 Lee, 2004, Spinal NF-kB activation induces COX-2 upregulation and contributes to inflammatory pain hypersensitivity, Eur. J. Neurosci., 19, 3375, 10.1111/j.0953-816X.2004.03441.x Kolls, 2004, Interleukin-17 family members and inflammation, Immunity, 21, 467, 10.1016/j.immuni.2004.08.018 Dinarello, 1996, Biologic basis for interleukin-1 in disease, Blood, 87, 2095, 10.1182/blood.V87.6.2095.bloodjournal8762095 Martinez-Fernandez de la Camara, 2015, Adalimumab reduces photoreceptor cell death in a mouse model of retinal degeneration, Sci. Rep., 5, 11764, 10.1038/srep11764 Palframan, 2009, Use of biofluorescence imaging to compare the distribution of certolizumab pegol, adalimumab, and infliximab in the inflamed paws of mice with collagen-induced arthritis, J. Immunol. Methods, 348, 36, 10.1016/j.jim.2009.06.009 Brand, 2007, Collagen-induced arthritis, Nat. Protoc., 2, 1269, 10.1038/nprot.2007.173 Zhou, 2015, SND-117, a sinomenine bivalent alleviates type II collagen-induced arthritis in mice, Int. Immunopharmacol., 26, 423, 10.1016/j.intimp.2015.04.006 Furst, 2014, Rheumatoid arthritis pathophysiology: update on emerging cytokine and cytokine-associated cell targets, Rheumatology (Oxford), 53, 1560, 10.1093/rheumatology/ket414